- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06139536
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BAT4706 Injection Combined With BAT1308 Injection in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Cuiyu Li
- Phone Number: 15068858368
- Email: cyli@bio-thera.com
Study Contact Backup
- Name: Zhaohe Wang
- Phone Number: 13318818667
- Email: Zhwang@bio-thera.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Suxia Luo
- Phone Number: 18638553211
- Email: luosxrm@163.com
-
Zhengzhou, Henan, China, 450052
- Not yet recruiting
- The First Affiliated Hospital of Henan University of Science and Technology
-
Contact:
- Zhiye Zhang
-
-
Shandong
-
Linyi, Shandong, China, 276002
- Not yet recruiting
- Linyi Cancer Hospital
-
Contact:
- Zhen Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary signing of informed consent.
Study population:
- Dose increasing stage:Patients with advanced malignant solid tumors who have been pathologically confirmed, have failed to standard treatment, or are intolerant to standard treatment.
Dose expansion stage: Divided into 3 queues:
- Queue A: Patient with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by pathology, failed to standard treatment, or are intolerant to standard treatment. And it must meet the following requirements: a) Previous PD-L1 test results have been obtained; Or b) Provide previously stored tumor tissue samples or fresh biopsy tumor lesion tissue for PD-L1 testing at the site before the first medication use;
- Queue B: Advanced microsatellite stable (pMMR/MSS) colorectal cancer confirmed by pathology, with disease progression after receiving at least 2 standard chemotherapy regimens/lines, and no liver metastasis or resection/ablation liver metastasis.
- Queue C: Patient with Hepatocellular carcinoma confirmed by pathology, refractory to at least 1 line of previous systemic treatment, and intolerant to this treatment.
- An evaluable tumor focus was necessary in the dose escalation stage, and at least one measurable tumor focus in the dose expanding stage(according to RECIST 1.1 standard).
- ECOG should be 0-1 in the dose escalation stage, and be 0-2 in the dose expanding stage.
- The expected survival period is more than 12 weeks base on the evaluation of the investigator.
- Enough organs, bone marrow reserve function.
- Female patients with fertility must undergo a serum pregnancy test during the screening period, and the result is negative. Patient must agree to take effective contraceptive methods to prevent pregnancy.
Exclusion Criteria:
- Have received any other clinical trial treatment or participated in a medical device clinical study within 4 weeks prior to the first administration of the study drug.
- Previously failed to receive CTLA-4 monoclonal antibody treatment.
- Received other tumor treatments within 4 weeks prior to the first administration of the study drug, such as chemotherapy, radiotherapy (palliative radiotherapy must be completed within 2 weeks prior to the first administration), targeted therapy/immunotherapy (with a minimum interval of 4 weeks or at least 5 half-lives, whichever is shorter), hormone therapy (excluding alternative therapy).
- Prior to the first administration of the investigational drug, there were still cases of AE caused by previous anti-tumor therapy that were greater than level 1 (CTCAE5.0).
- Having undergone major surgery (such as craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first administration of the study drug, major surgery is defined as a level 3 or 4 surgery; Individuals with a history of organ transplant surgery.
- Primary central nervous system tumor or symptomatic central nervous system metastasis, meningeal metastasis, or previous history of epilepsy. Excluding patients with central nervous system metastasis who are clinically asymptomatic or have symptoms but have been judged stable by investigator.
- If other malignant tumors have been diagnosed within the past 5 years, or if previous malignant tumors have been cured for less than 5 years, the first pathological diagnosis shall prevail. Except radical skin basal cell carcinoma, skin squamous cell carcinoma or carcinoma in situ (such as breast cancer in situ, cervical carcinoma in situ).
- Severe cardiovascular disease: Heart failure with a New York Heart Association(NYHA) rating of 2 or above, left ventricular ejection fraction (LVEF) less than 50%, unstable arrhythmia or unstable angina, uncontrollable hypertension (defined in this protocol as systolic blood pressure>150mmHg and/or diastolic blood pressure>100mmHg after treatment, although the optimal antihypertensive treatment is used).
- Patients with a history of autoimmune diseases (those who undergo thyroid hormone replacement therapy to control stable hypothyroidism can be included in the group); Patients who are using immunosuppressive agents or systemic or absorbable local hormone therapy to achieve immunosuppressive effects (dosage>10mg/day of prednisone or other therapeutic hormones) and continue to use the study drug within 2 weeks before the first administration.
- Active infections with clinical significance that require intravenous antibiotics, including active pulmonary tuberculosis patients.
- Patients with uncontrolled or requiring drainage of pleural, pericardial, or abdominal effusion.
- Individuals at risk of thrombosis or bleeding.
- Individuals infected with the following diseases: human immunodeficiency virus (HIV) infection; Treponema pallidum antibody positive; Active hepatitis B virus infected; Hepatitis C virus infected.
- Received or planned to receive live/attenuated vaccines within 4 weeks prior to screening or during the study period.
- Known to have experienced severe hypersensitivity reactions to any monoclonal antibody.
- Patients who have a known history of abuse or drug use of psychotropic substances and are believed to affect compliance with this study.
- Pregnant or lactating women.
- The study participants who were considered unsuitable for the study by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A/ Standard 3+3 1.0mg/kg of BAT4706 with 300mg of BAT1308
Drug: BAT4706 injection, Dosage: 1.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month. Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year. |
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
|
Experimental: B/ Standard 3+3 2.0mg/kg of BAT4706 with 300mg of BAT1308
Drug: BAT4706 injection, Dosage: 2.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month. Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year. |
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
|
Experimental: C/ Standard 3+3 3.0mg/kg of BAT4706 with 300mg of BAT1308
Drug: BAT4706 injection, Dosage: 3.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month. Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year. |
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
|
Experimental: D/ Standard 3+3 6.0mg/kg of BAT4706 with 300mg of BAT1308
Drug: BAT4706 injection, Dosage: 6.0mg/kg, Frequency: once every 3 weeks, Duration: 3 month. Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year. |
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
|
Experimental: E/ Standard 3+3 10.0mg/kg of BAT4706 with 300mg of BAT1308
Drug: BAT4706 injection, Dosage: 10mg/kg, Frequency: once every 3 weeks, Duration: 3 month. Drug: BAT1308 injection, Dosage: 300mg, Frequency: once every 3 weeks, Duration: 1 year. |
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle.
In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day.
Maintain administration of BAT1308 monotherapy after four cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: The first administration cycle(21 days)
|
The following AEs related to the study drug occurred from day 1 to day 21 after administration in the first cycle: ≥grade 3 of non hematological toxicity (except for nausea, vomiting, and diarrhea that can be relieved within 3 days of supportive treatment, and those who recover within 2 hours of symptomatic treatment of infusion reactions); ≥grade 4 of Hematological toxicity(including ≥ 3 grade neutropenia with fever; however, grade 4 neutropenia requires a duration of ≥ 7 days to determine DLT);≥ grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding. |
The first administration cycle(21 days)
|
Vital signs
Time Frame: Through study completion, 1 year
|
Number of cases with abnormal vital signs results
|
Through study completion, 1 year
|
Physical examination
Time Frame: Through study completion, 1 year
|
Number of cases with abnormal physical examination results
|
Through study completion, 1 year
|
Laboratory Examination
Time Frame: Through study completion, 1 year
|
Number of cases with abnormal laboratory examination results
|
Through study completion, 1 year
|
Electrocardiogram
Time Frame: Through study completion, 1 year
|
Number of cases with abnormal electrocardiogram results
|
Through study completion, 1 year
|
Echocardiography
Time Frame: Through study completion, 1 year
|
Number of cases with abnormal echocardiography results
|
Through study completion, 1 year
|
Adverse event
Time Frame: Through study completion, 1 year
|
Number of cases with all adverse medical events that occur after the subject receives the investigational drug assessed by CTCAE V5.0
|
Through study completion, 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic
Time Frame: Every cycle until 18 cycles (one cycle equals 3 weeks)
|
Cmax
|
Every cycle until 18 cycles (one cycle equals 3 weeks)
|
Immunogenicity
Time Frame: Every cycle until 18 cycles (one cycle equals 3 weeks)
|
Presence of anti drug antibody (ADA)/Neutralizing antibodies (NAb)
|
Every cycle until 18 cycles (one cycle equals 3 weeks)
|
Objective response rate (ORR)
Time Frame: Through study completion, 1 year
|
Refer to the proportion of subjects defined as complete remission (CR) and partial remission (PR)
|
Through study completion, 1 year
|
Best Overall Response Rate(BORR)
Time Frame: Through study completion, 1 year
|
The proportion of subjects with complete response (CR) and partial response (PR) as the optimal ORR in tumor efficacy evaluation
|
Through study completion, 1 year
|
Progression-Free Survival(PFS)
Time Frame: Through study completion, 1 year
|
The time from the first administration to the occurrence of objective tumor progression or all cause death
|
Through study completion, 1 year
|
Duration of Response(DOR)
Time Frame: Through study completion, 1 year
|
DoR is defined as the time between the first assessment of objective remission of a tumor and death from any cause before the first assessment of Disease progression (PD) , reflecting the duration of ORR.
|
Through study completion, 1 year
|
Overall Survival(OS)
Time Frame: Through study completion, 1 year
|
The time from the date of first administration to the occurrence of death due to any cause.
Subjects who were still alive at the time of analysis will use the date of their last contact as the deadline.
|
Through study completion, 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suxia Luo, Henan Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAT-4706-1308-001-CR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on BAT4706 Injection
-
Bio-Thera SolutionsPeking University Cancer Hospital & InstituteRecruitingMelanoma | Advanced Solid TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
National Taiwan University HospitalCompleted